-specific and vimentin 59-71 -specific Cd4+ t cells were characterised by flow cytometry using peptidehistocompatibility leukocyte antigen (pHLA) tetramers. After sorting of antigen-specific t cells, tCrα and β-chains were analysed using multiplex, nested pCr and sequencing. results ACpA + rA in InA was independently associated with HLA-DRB1*14:02. Consequent to the His13βSer polymorphism and altered p4 pocket of HLA-drB1*14:02, both citrulline and arginine were accommodated in opposite orientations. oligoclonal autoreactive Cd4+ effector t cells reactive with both citrulline and arginine forms of vimentin [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] were observed in patients with HLA-drB1*14:02 + rA and at-risk ACpA -first-degree relatives. HLA-drB1*14:02-vimentin 59-71 -specific and HLA-drB1*14:02-vimentin64Cit 59-71 -specific Cd4+ memory t cells were phenotypically distinct populations. conclusion HLA-drB1*14:02 broadens the capacity for citrullinated and native self-peptide presentation and t cell expansion, increasing risk of ACpA+ rA.
IntrOductIOn
Rheumatoid arthritis (RA) is an autoimmune disease with peak incidence in the sixth decade and prevalence of 1% in Caucasians, linked to HLA-DRB1. HLA-DRB1 alleles associated with anticitrullinated peptide antibody (ACPA)-positive RA in Caucasians share a common motif in the third hypervariable region, the 'shared susceptibility epitope (SE)', which was shown to accommodate citrullinated (Cit) self-epitopes. [1] [2] [3] Citrulline is post-translationally modified from arginine during inflammation, endoplasmic reticulum (ER) stress and autophagy. 4 5 Various RA-associated Cit-autoantigens, recognised by ACPA, are present in inflamed sites, including joint tissues. Low-titre ACPA develops in healthy individuals associated with environmental risk factors including smoking and periodontitis, but are unrelated to HLA-DR SE. [6] [7] [8] [9] [10] [11] In the immediate pre-RA period, ACPA isotype diversity and titre increasea process associated with antigen-specific CD4+ T cell help for affinity maturation in germinal centres. 8 HLA-DR SE is associated with ACPA + RA rather than ACPA, implying that presentation of Cit-autoantigens bound to HLA-DR SE molecules to CD4 + T cells is associated with RA development in at-risk individuals carrying HLA-DR SE.
Based on genome-wide studies (GWAS) in patients of predominantly Caucasian and Asian ethnicity, HLA alleles associated with ACPA-positive RA, including HLA-DRB1*04:01, HLA-DRB1*04:05 and HLA-DRB1*01:01 (ORs of 2.17-4.44), were found to share a common motif at amino acid positions 11, 13, 71 and 74, influencing the P4 antigen-binding pocket of DRβ. 2 Moreover, Val11βSer and His13βSer polymorphisms within that motif were found in genomic studies to stratify with ACPA-negative RA in Caucasians. 3 The discovery that P4-Cit was accommodated but the positively charged Arg was excluded from the electropositive P4 pocket of HLA-DRB1*04:01/04 suggested that preferential presentation of Cit-autoantigens might underpin the association of ACPA + RA with the SE. 12 While HLA-DRB1*04:01-restricted CD4 + memory T cells recognising Cit-autoantigens have been reported in patients with RA, 12 Basic and translational research in disease development is unclear. To date it has not been determined how autoreactive T cells respond to Cit-autoantigen in RA and whether they undergo clonal expansion due to antigen experience in patients with RA or in HLA-SE + at-risk first-degree relatives (FDRs).
Furthermore, in unravelling antigen presentation by HLA-DR molecules in RA, the ethnic mix of the samples included in GWAS may skew interpretations of amino acids contributing to binding motifs made from genomic studies. The Indigenous North American (INA) population has a twofold to threefold higher prevalence of RA than Caucasians, with RA onset peaking earlier in the fourth decade of life.
14 Moreover, 90% of INA patients with RA are ACPA + . In this population, FDRs have a high prevalence of joint symptoms and of ACPA positivity, predisposing them to RA. 15 16 To date, the HLA association with RA in INA has been sought in studies of <100 patients. [17] [18] [19] These studies suggested that the HLA-SE alleles also predispose to RA in INA. HLA-DRB1*04:04 is the most frequent SE allele in these populations, followed by HLA-DRB1*14:02. Since HLA-DRB1*14:02 carries the β13Ser residue, which was interpreted to stratify with ACPA-negative RA, 3 we investigated the genetic and underlying molecular bases for the increased risk of severe ACPA + RA in INA.
MAterIAls And MethOds study participants
RA cases, non-RA controls and FDRs were recruited from INA populations in Central Canada (Cree, Ojibway and Ojicree) and Alaska Native people (from Southcentral and Southeast Alaska). DNA for HLA typing, serum and peripheral blood mononuclear cells (PBMC) were isolated.
hlA-drB1*14:02 expression and purification
Peptide-loaded HLA-DRB1*14:02 molecules were purified, crystallised and structures determined.
Multiplex AcPA assay
Serum levels of antibodies targeting 40 putative RA-associated autoantigens were measured using a custom bead-based immunoassay on a Bio-Plex platform, as previously described.
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tetramer staining and analysis of tcr repertoire
Tetramer staining and T cell receptor (TCR) repertoire analysis used previously published methods, with some modifications. 12 21 22 Details of all methods are available in online supplementary methods, supplementary Accommodation of arginine and citrulline residues within the P4 pocket of hlA-drB1*14:02
The HLA-DRB1 chain contains 12 polymorphic residues that have been directly implicated in peptide binding. 24 HLA-DRB1*14:02 differs from HLA-DRB1*04:01, HLA-DRB1*04:04 or HLA-DRB1*01:01 in eight of these residues, which shape P4, P6, P7 and P9 pockets (figure 2A). To test whether HLA-DRB1*14:02 presents autoantigens differently from HLA-DRB1*04:01, HLA-DRB1*04:04 or HLA-DRB1*01:01, we compared the capacity of each HLA binding pocket to accommodate Cit and Arg residues using the influenza-derived HA 305-319 peptide. [25] [26] [27] [28] Conversion of Arg to Cit at peptide positions interacting with P4 enhanced structures, Tyr, Ser and Arg occupied the P1, P6 and P9 pockets of HLA-DRB1*14:02, respectively (figure 3B,C). In the HLA-DRB1*14:02-fibrinogen β74Cit 69-81 complex, Tyr, Ala and Ala occupied the P1, P6 and P9 pockets of HLA-DRB1*14:02, respectively (figure 3D). The largest structural differences between the peptides in each binary complex centred on the residue occupying the P4 pocket of HLA-DRB1*14:02, namely P4-Cit and P4-Arg in vimentin-64Cit 59-71 , fibrinogen β74Cit 69-81 and vimentin-64Arg 59-71 , respectively. These structures clearly show that P4-Arg and P4-Cit are presented in alternative orientations, whereby the P4-Arg projects inwards, whereas the P4-Cit projects outwards from the HLA-DRB1*14:02 Ag-binding cleft ( figure 3F-H) . The P4-Arg is buried in the pocket to avoid interactions with the positively charged β71Arg residue. This orientation is promoted by β11Ser and β13Ser, whereupon these two small polar residues allow the accommodation of Arg by providing the necessary space and H-bonding partners (figure 3F). Larger residues in HLA-DRB1*04:01 (β11Val and β13His) and HLA-DRB1*01:01 (β11Leu and β13Phe) as well as the charge repulsion of β13His in HLA-DRB1*04:01 would prevent the accommodation of Arg at P4. 12 The P4-Arg residue is stabilised by H-bonds with Ser11β, Ser13β and Tyr30β, and a salt bridge with Glu28β ( figure 3F ). In contrast, the P4-Cit sits upright in both Cit-epitopes, similar to its orientation in P4-Cit from Cit epitopes presented by HLA-DRB1*04:01/04:04 Basic and translational research ( figure 3G,H) . 12 The P4-Cit is stabilised by H-bonds with Arg71β and Gln70β ( figure 3G,H) . Accordingly, we demonstrate a conserved positioning of the citrulline residue in two distinct epitopes that contrast the orientation of the non-Cit residue within the P4 pocket. Similar to its orientation in HLA-DRB1*04:01 and HLA-DRB1*04:04, 12 29 P4-Cit was solvent-exposed in HLA-DRB1*14:02 and could potentially interact with TCR.
Antigen-experienced, oligoclonally expanded t cells recognise Arg and cit variants of vimentin 59-71 presented by hlA-drB1*14:02
Although both vimentin-64-Arg and 64-Cit variant peptides bound HLA-DRB1*14:02, only P4-Cit sits upright, and thereby potentially able to interact with the TCR. Thus, we addressed whether autoreactive T cells with TCRs recognising one or both epitopes were present in the periphery and displayed evidence of in vivo expansion in response to antigen presentation. We analysed T cells recognising HLA-DRB1*14:02-vimentin-64Cit 59 figure 4D ). T cell effector function is balanced by the suppressive activity of Treg. 31 The ratio of The biased TCR usage suggests a structural requirement for conserved amino acid sequences to recognise vimentin 59-71 and vimentin-64Cit 59-71 . Nucleotide sequences encoding TRBV30 CDR3 reveal that although the second N region at the D-J junction in each TCR is different, they encode the same amino acid sequence (table 2) . These data implicate convergent recombination events in the selection of this sequence during TCR gene rearrangement. †Nucleotide sequences encoding each of the public CDR3β amino acid sequences, which require a minimal number of N or P additions to be produced. Nucleotides attributed by the germline Vβ, Dβ and Jβ genes are shown in blue, red and green, respectively. N-additions are in black and P-additions in purple text. The nucleotides at the D-J junction encoding the same amino acid are underlined in each case. FDR, first-degree relatives; RA, rheumatoid arthritis.
Basic and translational research
polymorphism and altered P4 pocket, HLA-DRB1*14:02 can present both variant peptides. This contrasts with structures of HLA-DRB1*04:01 and *04:04, in which Cit but not Arg can be accommodated in P4. 12 12 29 35 36 reinforcing that T cell function aligns with HLA-DR-peptide structure.
We show preferential variable gene segments and clonally expanded TCR among vimentin 59-71 -reactive and vimentin-64Cit 59-71 -reactive CD4 + CD25 + CD127 + Teff sorted from patients with RA and FDRs, including a public TRBV CDR3. These data suggest that presentation of vimentin self-epitopes in vivo continues in genetically predisposed individuals before and after onset of RA, and selects T cells making productive TCR rearrangements, as identified by the nucleotide sequences, for antigen recognition and T cell expansion.
Although limited by small sample numbers, the phenotypic profiles of 64-Cit and 64-Arg variant-specific autoreactive T cells appeared to be different. The fibroblast antigen, vimentin, has widespread tissue expression. 37 Vimentin 64-Arg-specific memory CD4+ T cells specifically expressed CD69. CD69 is a marker of recent activation or tissue residency and exposure to cytokines such as tumour necrosis factor (TNF), 30 suggesting that vimentin 59-71 -reactive T cells are activated in tissue inflammatory sites. NKG2D signifies Teff costimulatory function and is TNF-activated. 31 Intriguingly, our data suggest cross-reactivity of some TCRs for the 64-Cit and 64-Arg variants: cell frequency of each specificity was correlated, the public clonotype occurred in T cells reactive with each variant, and T cells expressing TCR P2F3 were activated with both tetramers. In general, coexpansion of T cells recognising Cit and Arg variants might be advantageous, for example, for cross-protection against infectious antigens requiring rapid immunity. [38] [39] [40] This suggests a hypothesis for persistence of HLA-DRB1*14:02 in the INA population, even though its molecular structure permits presentation of multiple self-antigens driving ACPA + RA. Low-titre ACPA develops in healthy individuals independent of HLA-DR SE, particularly in inflammatory contexts. 6-8 10 11 In HLA-DR SE + individuals, memory T cells driven by antigen experience would provide required B cell help for increased titres and epitope spreading in patients developing RA. 8 41 42 Since HLA-DRB1*14:02 broadens capacity for autoantigen presentation and T cell expansion, our study provides a mechanism for enhanced risk of early onset of ACPA+ RA in INA. 
